ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) reported Q2 2017 earnings this Morning, coming in at $0.98 per share, beating Wall Street’s estimates of $0.86 per Share. Revenue for the quarter came in at $44.80 million beating analyst estimates of $43.20 million
Analyst Coverage For ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
These are 1 Hold Rating, 3 Buy Ratings .
The current consensus rating for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is Buy (Score: 2.75) with a consensus target price of $66.75 , a potential (47.78% upside)Recent Insider Trading for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)
- On 8/22/2016 Arthur Przybyl, Insider, sold 37,455 with an average share price of $66.97 per share and the total transaction amounting to $2,508,361.35.
- On 8/8/2016 Robert W Schrepfer, VP, sold 12,500 with an average share price of $67.06 per share and the total transaction amounting to $838,250.00.
- On 12/18/2015 James G Marken, VP, sold 3,500 with an average share price of $43.26 per share and the total transaction amounting to $151,410.00.
- On 11/12/2015 Arthur Przybyl, CEO, bought 2,500 with an average share price of $40.95 per share and the total transaction amounting to $102,375.00.
- On 3/19/2015 James G Marken, VP, sold 15,000 with an average share price of $66.50 per share and the total transaction amounting to $997,500.00.
- On 9/15/2014 Ross J Mangano, Director, bought 3,000 with an average share price of $27.49 per share and the total transaction amounting to $82,470.00.
Recent Trading for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares of ANI Pharmaceuticals, Inc. closed the previous trading session at 43.50 down -1.67 -3.70% with 135,418 shares trading hands.